Resources

£20 million Series A financing underway to support development of lead product

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials.

Excelra has partnered with Orogen Therapeutics, an innovative DNA-Encoded Library (DEL) and AI-driven biotechnology company currently developing a portfolio of best-in-class small molecule treatments.

Innovating manufacturing processes is key to revolutionising access to advanced cell and gene therapies - this blog explores how Tolemy Bio's co-founders, Caelan and Alex, are leveraging cutting-edge technologies like AI, biochemical modelling, and omics data to overcome complex challenges and drive global scalability.

BIA today announces Blood Cancer UK as its charity partner of the year for 2025. This partnership demonstrates BIA’s commitment to driving meaningful change through collaboration.

Poolbeg Pharma announces key insights from its poster presentation at the 66th American Society of Hematology ('ASH') Annual Meeting and Exposition, San Diego, California.

Abselion, an innovator in automated analytical instrumentation that simplifies at-line protein quantification, has secured £6.6 million in Series A financing to bring its award-winning Amperia system to market.

With a new Labour Government in place, this year’s event set the stage for impactful collaboration with MPs and policymakers. Read on to learn how we’re keeping life sciences at the top of the agenda.

The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation committed to the advancement of cell and gene therapies has released its Good Manufacturing Practice (GMP) Report 2024.

Degree apprentice with AstraZeneca, Emily Butterworth, becomes the first Manchester Met apprentice to be highly commended in the Royal Society of Biology’s Apprentice of the Year Awards 2024.

Facility dedicated to cryopreservation of leukapheresis starting materials to support clinical and commercial cell-based therapy programs

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL

Rinri Therapeutics, which is focused on transforming hearing loss treatment with regenerative cell therapy, announces that the novel surgical procedure to be used for regenerative cell delivery in its first-in-human trial has been published in the prestigious journal Nature Scientific Reports.

Ikarovec’s seed round extension raises funds to continue advanced pre-clinical trials of novel gene therapies to treat blindness and major chronic eye disease.

This is part of a series of blogs focussing on hearing therapeutics from different sector perspectives. In this blog, Karen Steel shares her thoughts on what she perceives to be some of the biggest opportunities in relation to the development of new treatments for hearing loss.

eXmoor and Virica receive funding to improve AAV gene therapy manufacturing. Partners will develop formulations of VSEs™ and validate their ability to improve yields of adeno-associated vector (AAVs) at scale, lowering gene therapy costs at commercial scale. Virica and eXmoor will receive advisory services and funding through collaborative Canada-UK government program.

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies.

Enara Bio announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors.